BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Biosimilars
Artificial intelligence
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Thursday, March 28, 2024
Home
»
Newsletters
» BioWorld Asia
BioWorld Asia
Oct. 22, 2008
View Archived Issues
Sygnis Pulls in $24M in Rights Offering for Stroke Drug Trial
Underlining the value of having big backers in these straitened times, Sygnis Pharma AG unveiled an €18.3 million (US$24.4 million) rights offering that already is fully backed by its two largest shareholders. (BioWorld International)
Read More
Companies Doing 'Unimaginable' as Deal-Making Landscape Alters
Read More
Researchers Successfully Comb the Genome for Baldness Genes
Read More
Basilea Racks Up European Approvals for Alitretinoin
Read More
Pfizer, UCB Create New Firm with Help from Public Funding
Read More
Immutep to Carry Out Phase I Trial of ImmuFact IMP321 in U.S.
Read More
Firms Say Advanced Therapies Still Lack Clear EU Definition
Read More
Other News To Note
Read More